BioPharma Dive June 28, 2021
Sponsored content By Koneksa Health

During the height of the COVID-19 pandemic, numerous clinical trials were paused or transitioned, if possible, to virtual or hybrid clinical trials. These types of trials leveraged a variety of modalities, including telemedicine, remote visits, and various sensors or wearable technology.

Not all disease indications or types of trials are suitable for virtual or hybrid clinical trials, although often components of hybrid trials might be suitable for most studies. Wearables, for example, such as smartwatches and exercise monitors, can provide a wealth of real-time physiological data that can be applied to a broad range of investigations, ranging from preclinical studies to determine patient suitability, through Phase I, II and III clinical trials, and in post-approval studies for enhanced monitoring for...

Today's Sponsors

Transcarent
SalesSparx
Canton & Company

Today's Sponsors

Oscar
Curation Health

Today's Sponsor

TripleTree

 
Topics: Biotechnology, Digital Health, Patient / Consumer, Pharma, Pharma / Biotech, Provider, Technology, Wearables
Wearables for actigraphy measures in clinical trials
Opinion: With Covid-19 halting clinical trials, wearables could be key — but data ‘wild west’ gets in the way
Healthcare is ripe for full adoption of wearable drug delivery devices